Enzolytics Inc (ENZC)

[falon]

Here we go again marching down the avenue, 2 more days and will be through was a song we sung in Air Force Basic Training.

The reason for press releases is to provide shareholders and whomever would like to know information about the said company.

Based on your posts you don't read these.



Enzolytics Announces the Discovery and Patenting of 8 Newly Identified Conserved Target Sites on the HIV-1 Virus
Press Release | 03/08/2021
Production of monoclonal antibodies targeting these sites is in process. U.S. patent protection has been filed claiming these sites.

COLLEGE STATION,TX / ACCESSWIRE / March 8, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (the "Company") today announced it has filed for patent protection on the identified 8 conserved sites on the HIV-1 virus, some with over 98% conserved sequences. These applications will be extended to international filings under the Patent Cooperation Treaty (PCT) allowing the Company to seek patent coverage in 153 countries.

The identification of these conserved sites on the HIV-1 virus was accomplished using artificial intellects techniques analyzing the 87,336 HIV isolates now known. Significantly, the Company's primary anti-HIV monoclonal antibody previously produced and tested by the Company was verified as conserved across all 87,336 isolates analyzed. Additional testing of the recombinant form of the antibody (the parent antibody being designated as Clone 3) against multiple HIVAs reported earlier, the Company also has filed for patent protection on the identified 11 conserved, expectedly immutable sites (epitopes) on the Coronavirus against which it is producing targeted anti-SARS-CoV-2 monoclonal antibodies. Using computer analysis (Artificial Intelligence [AI]), the Company has screened more than 50,512 Coronavirus isolates currently known and identified conserved sites which expectedly are immutable. The 11 conserved sequences identified on the virus isolates curated have been identified on the basis that they are 97.68% to 99.29% conserved over the entirety of 50,512 Coronavirus isolates now sequenced which have been analyzed.

The Company is actively progressing to produce monoclonal antibodies against many other viruses. The proprietary methodically used by the Company will be employed to produce monoclonal antibodies against numerous other virus and using "AI", the Company is curating the know sequences of the following viruses and intends to both seek patent coverage and produce monoclonal antibodies targeting conserved sequences These viruses include:

HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA). Patent applications will be filed claiming the inventive findings. Patent claims will cover the discovered epitope/antigens, with proposed vaccine claims, antibody claims, and related prophylactic/therapeutic method claims relating to these identified epitope/antigens. isolates is underway at the University of Strasbourg in France.
https://www.otcmarkets.com/stock/ENZC/news/Enzolytics-Announces-the-Discovery-and-Patenting-of-8-Newly-Identified-Conserved-Target-Sites-on-the-HIV-1-Virus?id=292798

Enzolytics Announces the Discovery and Patenting of Eleven Newly Identified Conserved Target Sites on the SARS-CoV-2 Virus (Coronavirus)
Press Release | 02/22/2021
Production of Monoclonal Antibodies Targeting These Sites Is in Process in the Company's Texas Lab

COLLEGE STATION, TX / ACCESSWIRE / February 22, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced it has identified eleven conserved, expectedly immutable sites (epitopes) on the Coronavirus against which it is producing targeted anti-SARS-CoV-2 monoclonal antibodies. Using computer analysis (Artificial Intelligence [AI]), the Company's genetics and molecular biology data science team has now screened more than 50,512 Coronavirus isolates currently known and has identified conserved sites which expectedly are immutable. The 11 conserved sequences identified on the virus isolates curated have been identified on the basis that they are 98.71% to 99.29% conserved over the entirety of the 50,512 Coronavirus isolates analyzed.

The Company has filed a comprehensive patent application covering these discoveries. This initial application has been filed in the U.S. and will be extended to claim international patent coverage through the International Patent Cooperation Treaty (PCT) to which 153 countries subscribe. The patent coverage sought includes patent claims on the discovered epitope/antigens, vaccine claims, antibody claims, and related prophylactic/therapeutic method claims relating to the epitope/antigens.

Under U.S. and foreign patent laws, filing of a patent application constitutes reduction to practice of the claimed invention. Rights of priority to claimed inventions date from the date of filing of the U.S. application. This priority date will be accorded to the inventions claimed in supplemental U.S. and all foreign corresponding applications filed through the PCT. A PCT filing provides the basis for seeking coverage in any or all of the 153 member countries. The term of protection provided by such patent or patents will be 20 years from the effective filing date. The Company follows a rigorous and comprehensive patent strategy as patent protection is considered a strategic and significant asset of the Company.
https://www.otcmarkets.com/stock/ENZC/news/Enzolytics-Announces-the-Discovery-and-Patenting-of-Eleven-Newly-Identified-Conserved-Target-Sites-on-the-SARS-CoV-2-Vir?id=290842